普洛药业：公司近期与西安新通签署战略合作框架协议

Core Viewpoint - The company has signed a strategic cooperation framework agreement with Xi'an New Tong Pharmaceutical Research Co., Ltd. to collaborate in the fields of innovative drug research and development and contract development and manufacturing organization (CDMO) projects for a duration of ten years [1] Group 1: Agreement Details - The agreement aims to enhance the company's competitiveness in the CDMO business through complementary advantages [1] - This framework agreement does not involve specific transactions and will not have a significant impact on the company's operating performance for the current year [1] - The impact on future operating performance will depend on the signing and implementation of specific project agreements [1] Group 2: Intellectual Property and Responsibilities - During the collaboration, research results and related intellectual property will belong to Xi'an New Tong [1] - The company commits to using the relevant technologies and processes only within the scope of the cooperation and guarantees that the development results do not infringe on third-party rights [1] Group 3: Risks and Uncertainties - The specific cooperation matters will require separate agreements, and there is uncertainty regarding the ability to achieve substantial cooperation [1] - The progress of the collaboration may be affected by industry policies, market conditions, and other force majeure factors [1]